# Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

> **NCT06415773** · PHASE3 · COMPLETED · sponsor: **HighTide Biopharma Pty Ltd** · enrollment: 367 (actual)

## Conditions studied

- T2DM (Type 2 Diabetes Mellitus)

## Interventions

- **DRUG:** HTD1801
- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT06415773
- **Lead sponsor:** HighTide Biopharma Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-04
- **Primary completion:** 2025-06-13
- **Final completion:** 2025-07-25
- **Target enrollment:** 367 (ACTUAL)
- **Last updated:** 2025-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06415773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06415773, "Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06415773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*